Pre-revenue biotech with extended cash runway but no near-term catalysts — stock likely to trade on pipeline news flow and broader biotech sentiment. Watch for IND filings in 1H 2027 and any early data readouts from the ongoing PIKture-01 study.
Price Chart
Executive Summary
OnKure Therapeutics reported Q2 2026 net loss of $15.3M ($0.31/share) vs $15.4M ($1.14/share) in Q2 2025, with the per-share improvement driven by a ~3.7x increase in weighted average shares outstanding to 49.9M from the March 2026 $150M private placement. Cash, cash equivalents and marketable securities totaled $176.4M, expected to fund operations into 2029. Pipeline progress remains on track with IND submissions for next-generation PI3Kα inhibitors OKI-345 (breast cancer) and OKI-355 (vascular anomalies) planned for 1H 2027.
Key Financial Metrics
Key Facts
- Cash position: $176.4M as of June 30, 2026, providing runway into 2029
- Net loss of $15.3M in Q2 2026, nearly flat vs $15.4M in Q2 2025
- EPS of -$0.31 vs -$1.14 in prior year, improving only due to share count dilution from 13.5M to 49.9M shares
- R&D expenses flat at $12.6M; G&A increased to $4.3M from $3.7M
- No revenue, no product sales, no guidance provided
- IND submissions for OKI-345 and OKI-355 targeted for first half of 2027
- Pre-revenue clinical-stage biotech with no near-term catalysts beyond pipeline advancement
Financial Impact
Cash burn ~$15.7M per quarter; no revenue; EPS improvement purely mechanical from share dilution
Risk Factors
- No approved products or revenue; entirely dependent on successful clinical development
- Early-stage pipeline may fail to produce viable candidates
- Cash position supports only preclinical/IND-stage work; additional capital likely needed before commercialization
- OKI-219 (prior lead) discontinued; all resources now focused on unproven next-generation candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-332809 |
| Document: okur-20260804.htm | 0001193125-26-332809 |
| Document: 0001193125-26-332809-index-headers.html | 0001193125-26-332809 |
| Document: 0001193125-26-332809-index.html | 0001193125-26-332809 |
| Document: 0001193125-26-332809.txt | 0001193125-26-332809 |
| 8-K Data (Synthetic) | 0001193125-26-332809 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 18d ago | SC 13G | $2.30 | awaiting T+60 | — | $2.47 (+7.61%) |
Aug 4, 2026 11w ago | 8-K | $4.16 | awaiting T+60 | — | $2.47 (−40.50%) |
Apr 24, 2026 26w ago | S-3 | $4.99 $4.32 | ▲ +13.43% | ▲ +18.20% | $2.47 (+50.40%) |
Apr 21, 2026 26w ago | DEFA14A | $5.01 $4.20 | ▼ −16.17% | ▼ −20.95% | $2.47 (−50.60%) |
Mar 23, 2026 31w ago | Insider Cluster | $3.98 $4.29 | ▲ +7.79% | ▼ −5.27% | $2.47 (−37.81%) |
Mar 12, 2026 32w ago | Press Release | $3.78 $4.40 | ▲ +16.40% | ▲ +4.79% | $2.47 (−34.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers